Researchers in Taiwan, Korea and at Brookhaven Test a Quantum Attention Model on Merck's Alzheimer's Drug Verubecestat: arXiv 2610.04588, 3 October 2026
A quantum attention model tested on an Alzheimer's drug series
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
Merck stopped its large Alzheimer's trial of verubecestat early, a pill designed to block the enzyme BACE1, which helps produce the amyloid found in the brains of patients. The drug had been carefully refined molecule by molecule, yet in a trial involving 1,958 participants with mild-to-moderate disease it did not reduce cognitive or functional decline compared with placebo.
That chemistry now has a second life as a test set. On 3 October 2026 five researchers from National Yang Ming Chiao Tung University, KAIST, Taiwan's National Center for High-Performance Computing, Brookhaven National Laboratory and Taipei Medical University posted a study of quantum attention for drug discovery. They used the compound series that led to verubecestat as a case study, asking whether a model with a small quantum circuit inside it orders those molecules by potency the way the laboratory did. The same models were also scored on standard benchmarks, including whether a molecule can cross the blood-brain barrier.
The paper, "Variational Quantum Attention for Molecular Graph Learning," by Yu-Cheng Lin, Yu-Chao Hsu, Tai-Yue Li, Nan-Yow Chen and Samuel Yen-Chi Chen, is a preprint on arXiv (2610.04588) and has not yet been peer reviewed. For a pharmacologist, a hospital formulary lead or a research director weighing quantum computing claims in drug discovery, its value lies in how plainly it reports what changed and what did not.
Software that predicts molecular properties is already a routine filter in early drug discovery. Chemists draw large numbers of candidate structures, and models rank them for solubility, brain penetration or binding strength before anyone spends money on synthesis and testing. A poor ranking sends chemists after the wrong molecules. The question this paper asks is narrow and useful: what happens to such a model when one small part of it is replaced by a quantum circuit?
Chalmers, Lund and Jülich Designed Lattice-Protein Sequences on IBM's Torino Quantum Processor: What Physical Review Applied Published on 28 September 2026
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
Most drug-discovery stories about quantum computers ask a folding question: given a chain of amino acids, which shape will it settle into? Protein designers work the other way round. They start from a shape they want, a pocket that grips a drug or a surface that binds a virus, and search for a sequence of building blocks that will fold into it. A team from Chalmers University of Technology in Gothenburg, Lund University and the Jülich Supercomputing Center has now measured how far one of today's quantum processors gets on the first half of that design problem.
Their paper, "Designing lattice proteins with variational quantum algorithms", appeared in Physical Review Applied (volume 26, article 034065) on 28 September 2026, a year after a first preprint on arXiv in August 2025. Hanna Linn, Lucas Knuthson, Anders Irbäck, Sandipan Mohanty, Laura García-Álvarez and Göran Johansson compare two families of variational quantum algorithms on a task they call protein sequence optimization, and they run the more robust family on IBM's Torino quantum processor, a device built on IBM's Heron r1 chip. With circuit settings carried over from noiseless computer simulations, the hardware found the correct sequence in more than 10 percent of its attempts for 17 of the 22 test problems, including the three largest, chains of 27 to 29 units.
The test proteins are simplified models drawn on a flat grid, and the authors say so plainly. The paper is still a careful read for anyone who funds or buys computational chemistry. In one controlled setting, with every right answer known in advance, it shows where current quantum hardware helps on a design task, where it breaks down, and which engineering choices made the difference.
The test bed is the HP model, one of the oldest simplifications in protein physics. Each protein is a chain of beads on a two-dimensional square grid, and every bead is one of only two kinds. H beads are hydrophobic, the water-avoiding kind of amino acid that real proteins tend to bury in their core. P beads are polar. The energy of a folded chain drops by one unit for every pair of H beads that touch on the grid without being direct neighbors along the chain, so the model rewards a compact hydrophobic core. Real proteins have twenty kinds of amino acid, side chains and three dimensions, so the HP model is a laboratory for methods. Its great advantage is that for chains of up to 30 beads, exhaustive classical enumeration has already listed the exact answers, which lets researchers grade a new algorithm without guessing.
NYU's Tautomer-Predictor Skips Quantum Calculations and Flags 126 PDBbind Ligands: What the September 2026 Chemical Science Paper by Pan, Han, Han and Zhang Shows
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
A single hydrogen atom can sit in two places on the same drug molecule. When it moves, the pattern of single and double bonds shifts with it, and the molecule presents a different face to the protein it is meant to bind. Chemists call these interchangeable forms tautomers, and choosing the wrong one at the start of a computer-aided drug design project can distort the docking scores and free-energy estimates that follow.
A paper in the Royal Society of Chemistry journal Chemical Science, "Deep learning of tautomer stability from crystallographic proton positions" by Xiaolin Pan, Chao Han, Fengyang Han and Yingkai Zhang of New York University, published online in September 2026, attacks this problem with an unusual source of training data. The team mined hydrogen positions resolved in small-molecule crystal structures from the Cambridge Structural Database, built more than 1.1 million tautomeric states from them, and trained a graph neural network to predict tautomer stability directly from a molecule's two-dimensional structure. The authors state that the model needs no 3D conformers and no quantum-mechanical calculations, which is what makes it fast enough for structure-based drug discovery at library scale.
The quantum-medicine interest lies in what the network replaces. Quantum chemistry has long been the accurate but slow reference for deciding which tautomer a molecule prefers, and it is also one of the problems quantum computing companies cite when they pitch molecular simulation to pharmaceutical buyers. Here a classical model trained on experimental crystal data takes over a large part of that job on a single GPU node.
The results come from retrospective tests on public structure collections. The study screened no new compounds in the laboratory and involved no patients, and its training labels describe molecules in the crystal, which is a different environment from a protein pocket or blood plasma.
Simulated Quantum Annealing Ranked Known Drug Pairs First for Diabetes and Rheumatoid Arthritis: Ramos, Coutinho and Magano in Quantum Machine Intelligence, 23 June 2026
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
Three researchers from Porto and the German Aerospace Center have written drug-pair selection as an energy problem that a quantum annealer could solve, and tested it on diabetes, rheumatoid arthritis, asthma and brain tumors. In simulation, the lowest-energy answers were dominated by drug combinations that doctors already use, and one of the top new suggestions for rheumatoid arthritis matches a pairing that a 799-patient trial found to roughly double remission rates.
The paper, by Diogo Ramos, Bruno Coutinho and Duarte Magano, appeared open access in Quantum Machine Intelligence on 23 June 2026 as article 70 of volume 8. It builds on the Complementary Exposure idea from network medicine, turns it into an optimization problem, and samples answers with simulated quantum annealing, a classical computer program that imitates how quantum annealing hardware behaves. Its central test is how often validated drug combinations appear among the top-ranked answers when they make up less than a tenth of a percent of the candidates.
Combination therapy is standard across chronic disease and oncology, because two drugs together can allow lower doses and fewer side effects. The search space is the problem. With more than a thousand approved drugs and thousands of diseases, the number of possible pairs grows far faster than any laboratory or trial program can test them.
For a pharmacology team or a hospital formulary committee, the study offers a clear example of what quantum optimization can and cannot yet contribute to that search. The ranking method works in simulation on four diseases. No quantum computer was used, and the authors state plainly that their predictions are hypotheses for experts to examine.
China's Pharmaceutical Industry 15th Five-Year Plan, Reported 18 September 2026, Lists Quantum Computing for Drug R&D; the 2021 Plan Did Not
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
On 18 September 2026 Chinese business media reported that the Ministry of Industry and Information Technology and nine other central departments had issued a five-year plan for the pharmaceutical industry that lists quantum computing among the technologies the state wants applied to drug research. The predecessor plan of December 2021 listed artificial intelligence, cloud computing and big data for the same job, and the word quantum did not appear in its published text.
The underlying document, which this Monitor knows through the reports of it rather than from the notice itself, is the 15th Five-Year Plan for the pharmaceutical industry, filed as MIIT joint planning document 2026 number 210 and covering 2026 to 2030. In its passage on frontier technologies, as quoted by the business press, it asks industry, universities, research institutes and hospitals to speed up the use of artificial intelligence, quantum computing, supercomputing and computational medicine in drug research and development. The same plan sets a target that Chinese first-in-class drugs make up at least 25 percent of the global total by 2030.
A planning document is a statement of intent, not a result. For a reader who buys for a hospital or runs a pharmaceutical research group in Europe, its value lies in what it tells you about where Chinese public money, procurement and regulatory attention will go for the rest of the decade, and in the gap between the plan's language and the evidence a physicist in Shanghai asked the same industry to produce a week earlier.
The ten signatories are the Ministry of Industry and Information Technology, the National Development and Reform Commission, the Ministry of Natural Resources, the Ministry of Agriculture and Rural Affairs, the Ministry of Commerce, the National Health Commission, the Ministry of Emergency Management, the National Healthcare Security Administration, the National Administration of Traditional Chinese Medicine and the National Medical Products Administration.
Phasecraft's 3,000-Emulation VQE Molecular Dataset With NVIDIA Was Computed on GPUs Under Wellcome Leap's Q4Bio: What the 14 September 2026 Announcement Shows
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
Phasecraft and NVIDIA announced on 14 September 2026 what Phasecraft calls the largest known database of Variational Quantum Eigensolver results for molecules, more than 3,000 emulations across thirteen molecular systems, computed on NVIDIA Hopper GPUs at the University of Nottingham. No quantum computer ran any of it, and the announcement says so in its own description of the method.
The dataset is an emulated VQE molecular dataset: for each of the 13 molecular systems, a classical GPU cluster worked out what a quantum processor of 4 to 32 qubits would return when asked for the lowest-energy state of the molecule, with most of the circuits in the 24-to-28-qubit range. Its purpose is to train Phasecraft's quantum-enhanced density functional theory method, a way of improving the standard workhorse of computational chemistry with data a quantum computer would produce. The Wellcome Leap Q4Bio program that paid for it asks whether new algorithms can deliver quantum advantage for health, and its prizes require a demonstration on a real quantum computer with more than 50 qubits. For a hospital buyer or a clinical pharmacologist the announcement describes training data for a chemistry method, produced on conventional hardware, with no named molecular systems, quantitative accuracy benchmarks or clinical results disclosed.
The Phasecraft release, datelined London and Toronto, gives four numbers: over 3,000 unique emulations, 13 molecular systems, a qubit range of 4 to 32 with "the vast majority in the 24–28 qubit regime", and "a 15x simulation speedup over prior results when modeling physical, many-body systems integral to biology and health applications". The GPUs were NVIDIA Hopper hardware hosted at the University of Nottingham, driven through NVIDIA's cuQuantum software kit. Ashley Montanaro, Phasecraft's co-founder and chief executive, is quoted on the need "to push the limits of today's most capable hardware, both conventional and quantum"; Sam Stanwyck, NVIDIA's director of quantum product, on shortening "the timeline" to useful quantum computing. The release describes the dataset as "a training foundation for quantum-enhanced molecular modeling, which could accelerate drug discovery at a scale previously out of reach, as quantum hardware develops". The conditional clause at the end carries the weight of the sentence.
IonQ and Kipu Quantum's 64-Qubit Protein-Folding Paper Took Third Place at IEEE Quantum Week 2026: Six Peptides, 46 to 61 Qubits, Four of Six Reference Energies Reached After Classical Post-Processing
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
A Kipu Quantum and IonQ paper on lattice protein folding took third place in the hybrid case-studies track at IEEE Quantum Week 2026 in Toronto, IonQ announced on 15 September 2026, and the release says the work "was used to improve computational speed and accuracy in drug discovery." The paper, on arXiv since 29 April 2026, reports something narrower: a hardware benchmark on six short peptides that reached the reference energy of a conventional solver in four cases, and only with the help of a classical consensus step.
The experiment ran six peptides of 14 to 16 residues through a 64-qubit trapped-ion processor, a barium development system IonQ describes as similar to its forthcoming Tempo line, folding each on a coarse lattice with no side chains using 46 to 61 qubits. The quantum circuits produced samples that mostly violated the backbone geometry, and it took a classical post-processing step, a consensus vote over the two thousand lowest-energy samples combined with a pool of feasible backbones, to reach the reference energy in four of the six cases; a random-start version of the same pipeline reached it in one. For a hospital buyer or a clinical pharmacologist that is the whole result: a hardware run on a benchmark, at a scale that a classical genetic algorithm solves to convergence, with the quantum contribution visible in the statistics of one part of the problem.
The IonQ release counts 857 submissions and 27 Best Paper honors at the conference, four of which went to papers with IonQ authors. Three of the four concern AI fine-tuning, distributed optimization with Oak Ridge National Laboratory and NVIDIA, and linear algebra with Synopsys. The fourth is the protein-folding paper with Kipu Quantum, which the release assigns to drug discovery. The conference's award list gives the paper third place in the Quantum End-to-End Hybrid Case Studies track, with the paper presented on Monday 14 September and the track's awards presented on Tuesday 15 September. Five of the fourteen authors are at Kipu Quantum in Berlin, one, Sebastián Romero, at ICMM-CSIC and the Autonomous University of Madrid, and eight at IonQ, among them Martin Roetteler, IonQ's vice president of quantum applications research, who is quoted in the release. The award recognizes a conference paper; it does not evaluate a drug, a target or a clinical claim, and the paper makes none.
AOI Biosciences' Roughly 500 Million Yen Financing and Share Transaction of 14 September 2026 Lists Its Neo-Self Antibody Test Ahead of the Toshiba SQBM+ Quantum-Inspired Drug Platform
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
On 14 September 2026 AOI Biosciences, a diagnostics and drug-discovery company in Ibaraki, Osaka Prefecture, announced a financing and secondary-share transaction of roughly 500 million yen with existing and new investors; the company says the new-share portion takes its cumulative funding to about 1 billion yen, and it does not state how much of the 500 million is new money. The release describes two core businesses. One is a blood test for a "neo-self" autoantibody that is already sold to more than 300 Japanese medical institutions. The other is an allosteric drug-discovery method built with Toshiba on the quantum-inspired SQBM+ solver, the method whose patent Toshiba announced on 3 September and this Monitor examined on 6 September.
The release lists three planned uses for the proceeds, and that list is the useful fact for a hospital buyer or a pharma partner, with one caution: the order says nothing about how much money goes where or which business the company values more. The neo-self antibody test fills the first two entries, with domestic roll-out, Asian expansion and new autoimmune indications, and further research investment in the quantum-inspired drug discovery platform is the third. No amounts are attached to any entry. The clinical figures the release cites for the test, a pregnancy rate more than doubled and a live-birth rate 1.7 times higher, come from two Frontiers in Immunology cohort studies whose treated and untreated groups can be counted, and this note counts them.
Lu Chaoyang Called "Quantum New Drugs" a Packaged Product at the 2026 Bund Summit; Califano Calls Cancer "Quantum" as an Analogy
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
In September 2026 the word "quantum" reached medicine from two directions, and the contrast is instructive for anyone who buys for a hospital or a drug company. In Shanghai, the physicist Lu Chaoyang told the 2026 Bund Summit that some Chinese companies sell "quantum new drugs" as finished products while leading research teams still offer prize money for a practical quantum algorithm. In New York, Columbia University published a feature on 26 August in which the cancer biologist Andrea Califano called cancer a "quantum disease", a comparison with electron energy levels and no quantum hardware in it.
Califano's phrase points at two Nature Genetics papers, a pancreatic cancer dataset of hundreds of thousands of single cells, and a testable count of six cell states. The quantum new drugs that Lu Chaoyang objected to are described in a Xinmin Evening News commentary of 11 September as marketing, and the commentary supplies no product-level evidence for a buyer to assess. It also asked why the correction had to come from a scientist and why no industry regulator has set a standard for what a company may call quantum. That is the question a buyer should put to a vendor before any contract is signed.
KRIBB and Quandela Signed a Memorandum in Paris During Meetings on 7 and 8 September 2026 to Apply Photonic Quantum Computing to Drug-Candidate Discovery
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
During meetings in Paris on 7 and 8 September 2026, the Korea Research Institute of Bioscience and Biotechnology signed three memoranda of understanding, one of them with Quandela, the photonic quantum computing company founded in 2017 on research from CNRS and Université Paris-Saclay. KRIBB announced the agreements on 10 September, and the Korean daily Herald Economy carried the institute's account the same day. The signing took place during President Lee Jae-myung's state visit to France; on 8 September, Korea's science ministry and France's economy ministry exchanged a government-level memorandum on artificial intelligence, semiconductors and quantum technology at the Élysée.
The KRIBB and Quandela agreement has one stated purpose: to combine artificial intelligence and quantum computing with biological research so that finding a drug candidate takes less time and money than it does today. KRIBB puts the usual time to discover a candidate at more than ten years. The public announcement does not disclose a molecule, a disease target, a budget or a delivery date, and Quandela's own product pages describe the two machines it documents in use, Lucy at the French national computing center TGCC and Belenos in its cloud, as 12-qubit photonic machines. Read together, those two facts set the honest expectation for this partnership: a research collaboration at the stage of a signed memorandum, with no demonstrated pipeline benefit yet and no published plan for producing one.
The Minimal-Basis Run Gave T4-Lysozyme the Wrong Binding Sign: What Cleveland Clinic, RIKEN and IBM Changed to Correct It
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
On 9 September 2026 Cleveland Clinic announced that a team from Cleveland Clinic, the RIKEN Center for Computational Science and IBM had reached the finals of the 2026 ACM Gordon Bell Prize, for quantum-classical electronic-structure calculations on protein-ligand complexes of 11,608 and 12,635 atoms. Four days earlier the preprint behind that entry gained a second version, and buried in it is a result that deserves more attention than the atom count.
When the team computed the binding energy of a well-studied protein-ligand pair in a minimal basis set, the answer came out too positive, which is to say it pointed the wrong way for a ligand known to bind. Recomputing it with richer orbitals in the binding region and a tighter bath threshold together corrects the sign of the binding energy, at about ten times more in total node-hours. The revision also reports a first end-to-end wall-clock time, 62.4 hours from fragment generation to energy reconstruction, for a bound-complex ground-state run.
Japanese Patent 7,908,389, Registered 10 August 2026: What Toshiba and AOI Biosciences Claim for Allosteric Site Prediction, and What Quantum-Inspired SQBM+ Actually Runs On
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
On 3 September 2026 Toshiba Corporation and AOI Biosciences announced that a patent the two companies had filed together was registered in Japan on 10 August 2026. It covers an allosteric pathway prediction device: software that reads a protein's three-dimensional structure and predicts the internal routes leading to pockets that sit away from the site where the protein does its work.
Three parts of that announcement carry different weights. Japanese Patent 7,908,389 is a legal instrument whose protection runs to its granted claims in Japan, which is a separate question from whether the method finds sites nobody had found before. The supporting evidence offered in the release is one figure, accuracy of 80 percent or higher on already-known sites, reported without a definition of accuracy, a benchmark set or a paper behind it. And the optimization engine at the center of the work, Toshiba's SQBM+, is described as quantum-inspired, a term that here means the solver runs on ordinary classical computers and uses no qubits.
Quantum Foundry Copenhagen Plans a 5,300-Square-Meter Quantum Chip Factory for 2027: What the Novo Nordisk Foundation Announced on 4 September 2026
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
A health foundation announcing a chip plant is unusual enough to state plainly. On 4 September 2026 the Novo Nordisk Foundation and Quantum Foundry Copenhagen, the company the foundation started in 2023 and owns, said they will build a 5,300-square-meter quantum chip fabrication facility in Copenhagen, with an opening expected in 2027. The plant is to combine nanofabrication of quantum materials, characterization, testing, chip assembly and packaging, and it is to sell wafer fabrication to quantum technology vendors elsewhere in the world on commercial terms.
The foundation's own Danish announcement puts faster development of new medicine among the reasons for spending the money. Its total commitment to quantum technology now exceeds DKK 2.9 billion, about EUR 390 million, and the factory is the manufacturing end of it. Two days earlier the engineering firm Ramboll handed over the Copenhagen building that will house Magne, the machine the foundation co-owns through QuNorth. Both projects run toward the same declared destination, a fault-tolerant quantum computer in Denmark before 2034, and a clinician reading the announcement is entitled to ask what any of it does for a patient in the meantime.
BC World Pharm Announced on 1 September 2026 That It Was Selected With Qunova Computing to Target Pan-Beta-Lactamase and Penicillin-Binding Proteins
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
An infectious disease physician facing a resistant Gram-negative infection chooses among a small number of remaining drugs. The reason the number is small is chemical. Bacteria carrying beta-lactamase enzymes cut the beta-lactam ring before the antibiotic reaches the protein it was meant to block. One clinical strategy has been to pair the antibiotic with an inhibitor that protects it, and that strategy keeps running out because the approved inhibitors do not cover every enzyme.
On 1 September 2026 BC World Pharm announced that it had been selected as lead research institution for a Korean government project intending to find compounds that hit pan-beta-lactamase and penicillin-binding proteins at the same time, with Qunova Computing, a quantum computer based computational chemistry company, as co-research institution. The cited announcements state no budget or project term, and no ministry award record was reachable during this reading.
The two targets do different jobs. Penicillin-binding proteins build the bacterial cell wall and are what every beta-lactam antibiotic is aimed at. Beta-lactamases are the defense the bacterium evolved against exactly that, and they fall into four Ambler classes, three of which cut with a serine residue while class B uses zinc. Hamrick and colleagues place clavulanic acid and tazobactam mainly against class A, describe avibactam as reaching classes A, C and D, and report that no inhibitor approved as of 2020 covered both the clinically important serine enzymes and the metallo enzymes. Their own subject, taniborbactam, reached all four classes with one documented exception, IMP-1. Those limits sit alongside the World Health Organization's priority pathogens list of May 2024, which puts carbapenem-resistant Enterobacterales in its critical group.
Qunova Computing was founded in 2021 by a KAIST professor and is based in Daejeon; the company reports that its HI-VQE algorithm has run quantum chemistry problems at qubit counts up to 68 and sits in IBM's Qiskit functions catalog. The announcement describes AI and quantum mechanics based multi-target design without identifying a method, a backend or a hardware result, and quantum mechanics based design is also standard vocabulary for classical quantum chemistry, which limits what can be inferred about quantum-hardware involvement. This is the second reported Korean selection in a week pairing a pharmaceutical company with a computational drug-design company, after D&D Pharmatech and Quantum Intelligence on 28 August, and the two run under different ministry instruments.
QC Ware and IonQ Mapped Four Orbitals of a Cytochrome P450nor Active Site Onto Eight Qubits of IonQ Forte on 1 September 2026
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
How tightly a candidate binds its target is one important factor in whether a drug works, and metal centers are among the difficult cases to calculate: an iron atom sitting in the middle of an enzyme. On 1 September 2026 QC Ware and IonQ said they had measured a four-orbital slice of one such site on a quantum computer and landed close to the classical answer. QC Ware's Promethium platform did the classical preparation, IonQ's Forte trapped-ion processor took the quantum measurement through Amazon Braket, and the target was the heme active site of cytochrome P450nor. The workflow calculated an electrostatic interaction energy within 0.5 kcal/mol of classical benchmarks, roughly four percent, inside the one kcal/mol threshold conventionally called chemical accuracy.
The IonQ half of a workflow already run on IBM hardware
This is a follow-up. On 7 August 2026 this Monitor read the same QC Ware Promethium workflow running a nitric oxide reductase calculation on IBM's 156-qubit Heron processor. The platform, the enzyme family and the hybrid division of labor are unchanged; the processor underneath is what is new, which makes hardware portability the company's actual claim. Portability is not comparability: the August disclosure carried no numerical result that today's figure could be set against. Today's release adds four disclosures the August account did not carry: the 115-atom active-site model, its more than 1,000 molecular orbitals, the reduction to a four-orbital active space mapped onto eight qubits, and the 0.5 kcal/mol comparison itself.
What the quantum machine actually did
The quantum step ran on eight qubits of a 36-qubit machine, measuring a four-orbital slice carved out of a model containing more than a thousand molecular orbitals. Promethium built the model, identified the strongly correlated region, reduced it automatically to that active space, and computed the final interaction energies classically after Forte measured the qubits in a single basis. Everything before and after the quantum slice happened on classical hardware.
Which enzyme, and why the framing needs care
P450nor sits in the cytochrome P450 superfamily whose monooxygenase members carry out most human drug metabolism, and the release says exactly that. P450nor itself is something else: a fungal CYP55 nitric oxide reductase, characterized in Fusarium oxysporum among other fungi, reducing nitric oxide to nitrous oxide and taking its electrons straight from reduced nicotinamide adenine dinucleotide, NADH. The release names no organism and no accession. It is a well-characterized computational test case, which is a good reason to choose it for a hardware demonstration and a poor reason to describe the run as modeling human drug metabolism.
What the result can and cannot establish
The comparison target was a classical benchmark, so the classical answer existed first, and the companies report agreement for this known case. The announcement names no preprint, reports no shot count, gives no uncertainty on the 0.5 kcal/mol figure and does not identify which classical method produced the benchmark.
A*STAR Put an 18-Variable Drug-Docking Problem on Six Qubits of IBM's ibm_kingston
Six qubits for an eighteen-variable docking problem
On August 20, 2026 six researchers at institutes of Singapore's Agency for Science, Technology and Research, the National University of Singapore and Nanyang Technological University posted a preprint describing a hybrid quantum-classical method for molecular docking, and executed its circuits on IBM's ibm_kingston processor. Molecular docking is the everyday question of early drug research: given a candidate molecule and a target protein, how does the molecule seat itself in the pocket, and how well. The team recast that question as a graph problem, where each plausible contact between ligand and protein is a weighted vertex and the winning binding pose is the heaviest set of contacts that can all coexist.
An encoding that carries three variables on one qubit
The contribution is an encoding the authors call full-basis encoding, which uses all three orthogonal directions of a qubit's Bloch sphere to carry information instead of one. That put an 18-variable problem on six qubits for the streptavidin-biotin complex 1STP, and a 14-variable problem on five qubits for trypsin with benzamidine, entry 9AW2. The paper also proves that a global minimizer of its objective can always be chosen to be a pure product state, so the optimum requires no entanglement between qubits and the circuits can stay shallow enough for current hardware. What changed for a reader tracking this field is the qubit cost of a docking problem, since the number of good qubits a problem consumes is the binding constraint on machines available today.
What the hardware runs did and did not settle
On both instances the runs on ibm_kingston recovered the same vertex selections as the classical simulation and matched the known clique structure under realistic gate noise and readout error. The authors state plainly that this is evidence of feasibility and that quantum advantage is not demonstrated, since both test problems were deliberately kept small enough for classical verification. Streptavidin with biotin and benzamidine in the trypsin pocket are textbook complexes, though their records differ in age: entry 1STP has been public since 1992, while entry 9AW2 is a 2025 redetermination of a complex first characterized in the mid-1970s. Either way the correct answer was known before the circuits ran, which is what made the check against ground truth possible and also what limits the claim. The open question the authors name themselves is whether the compression ratio survives realistic docking graphs with hundreds of vertices, alongside better ansatz design and hardware-aware circuit compilation.
A Tenth of a Cent per Guess, and No Qubits in the Loop
A tenth of a cent per ranked pair
On August 19, 2026, SandboxAQ made a virtual screening model called AQPotency generally available. The company's release says it scores how strongly a candidate molecule is likely to act on a disease target, ranks molecule and target pairs in seconds, runs on ordinary computing hardware, and costs as little as one dollar per thousand comparisons. At the advertised minimum, a million pairwise rankings come to about a thousand dollars. Screening at that price stops being a budgeted event a team plans around and becomes something a chemist can run while thinking.
Screening without a solved protein structure
The claim that will interest a hospital pharmacologist sits one line further down. AQPotency is described as working without a solved protein structure, which makes it structure-free potency prediction: the model does not need a crystallographic or cryo-electron map of the target before it will score anything. A great many disease targets have no such map, and programs aimed at them have historically stopped at that wall. Cheap ranking only helps if the ranking is right, and the release publishes no accuracy figures. What it offers instead is eight customer programs with what the company calls experimentally validated impact, plus named academic collaborations. No independent evaluation, no prospective blinded benchmark and no head to head against an established free-energy method appears in the launch material.
The Parkinson's campaign has its own preprint
The launch quotes Gary Miller of Columbia University's Mailman School of Public Health on selective binders for SV2C, a synaptic vesicle protein implicated in Parkinson's disease. That campaign was posted to bioRxiv the same day, with a SandboxAQ corresponding author and Miller as final author. Its methods matter: because no full-length SV2C structure existed, the team built a homology model from SV2A cryo-electron microscopy templates, ran molecular dynamics, and applied a convolutional neural network scoring function inside a funnel that narrowed 5.96 million commercial compounds to 3.19 million before docking. Of 94 prioritized candidates, 71 were profiled and 22 were active. It is a genuine result on a target with no selective probes, and it is neither an AQPotency run nor a structure-free one.
The pillar field reads not applicable
Nothing in this announcement runs on a quantum computer. The most operationally ready development in today's quantum medicine pool comes from a company the quantum trade press covers closely, and the tool is classical software on conventional machines. One day later, a separate group posted a preprint on loading a molecule's wavefunction onto qubits at all, which is the step before any quantum chemistry happens. Both belong in the pool, and they sit at opposite ends of the readiness ladder.
When the Error Check Happens Decides What It Buys
A 54 percent error cut, and what it was measured on
Simulating a molecule on a quantum computer means chopping its time evolution into many short slices, a technique called Trotterization. Accuracy improves as the slices get finer, and finer slices make a deeper circuit, and every additional gate in that circuit is another chance for a physical fault. Depth is what the chemistry asks for and depth is what today's hardware punishes, which is the bottleneck the field calls the deep Trotter dilemma.
A preprint from IonQ, qBraid and NVIDIA, posted in May 2026 by James Brown, Jason Iaconis, Yuri Alexeev and colleagues, reports that a combination of the Generalized Superfast Encoding, Clifford Noise Reduction and Shor-style stabilizer verification lowered the logical error rate by up to 54 percent on a trapped-ion machine. The encoding itself carries no such requirement, and Clifford Noise Reduction can be run with its stabilizer readout deferred; what the paper establishes is that the advantage over the unprotected baseline depended on mid-circuit measurement, the ability to read some qubits partway through a run, learn from them and continue with the rest.
What the number does and does not cover
The unprotected baseline is a six-qubit encoded Clifford Trotter step; the protected implementation that produced the 54 percent figure is wider, at 26 qubits and 580 gates, the extra width being the verification machinery itself. Both ran on a Barium development system similar to IonQ's forthcoming Tempo line. Clifford circuits are the well-behaved subset of quantum operations an ordinary laptop can simulate exactly, which is what makes them useful test articles: the correct answer is known in advance, so any deviation is measurable error. No molecule, binding energy or reaction barrier appears anywhere in the result, while IonQ's own account presents the same figure alongside the prospect of lower research costs and shorter time to market.
The control arm is the transferable finding
Keep the verification structure but move the stabilizer readout to the end of the circuit and it still beats having no error detection at all. What it stops doing is beating the unprotected baseline by a statistically significant margin for a single stabilizer round. Only the mid-circuit version clears that bar, which points at the timing of fault detection as the operative ingredient. For scale, published resource estimates for computing spin gaps in models of the cytochrome P450 catalytic cycle, a methodology benchmark and not a dosing or interaction predictor, run near 1,434 logical qubits and roughly 4.6 million physical qubits over 73 hours, on stated and assumption-dependent compilation figures. This Monitor records the work at TRL 3 on the simulation pillar.
A Paid Quantum Drug Project Meets a Four-Stage Validation Ladder
The next calculation became funded work
China Securities Journal reported on August 14 that Shenzhen Jingtong Life Science tested Boson Quantum's approach on a drug-target structure problem in June and moved to a paid quantum drug-discovery engagement in July. The client named two difficult tasks: finding the precise binding conformation of a drug-target complex and calculating its energy after binding. It also reported an advantage in conformation search. The work now covers new molecules associated with healthy aging. The article says drug-related intellectual property would be jointly owned if the project succeeds, while software and algorithm rights would remain with Boson. The account is commercially meaningful because a buyer has funded a defined computational problem, yet the public article provides no molecule list, hardware configuration, classical baseline, runtime, success metric, or laboratory confirmation.
The same report sets a demanding standard
GuoDun Quantum executive Wang Zhehui supplied a four-stage validation ladder in the same article. It begins with benchmark advantage and initial industry validation on real quantum hardware. The decisive stages are superiority to classical algorithms under equal conditions and reproducible business outcomes. The engagement is commercially concrete, but the disclosed record cannot yet assign it a validation rung because real-hardware use and a controlled comparison remain undisclosed. Funded work may support learning, access, feasibility, or method development. It establishes customer demand without settling the scientific comparison.
The medical handoff remains ahead
Quantum computation would sit near the beginning of drug development. It may help decide which molecules deserve synthesis and testing, though it cannot establish safety, dosage, biological effect, or clinical benefit. Quentir reads the account as a useful commercial milestone with a built-in limit. The reported planned IP allocation recognizes a reusable computational method on one side and, if the project succeeds, a medicine that must survive laboratory, preclinical, and clinical work on the other. Paid work has started before a reproducible pharmaceutical result. The next public milestone that changes the judgment would connect an equal-condition computational comparison to a wet-lab result that another team can understand and repeat.
A Photosensitizer Has Two Jobs Before Quantum Computing Helps
Two molecular jobs define the target
A light-activated cancer drug must absorb light in a useful therapeutic window and turn that energy into chemistry that damages a tumor. Xanadu and the University of Alberta announced on August 13 that they will develop quantum algorithms for photosensitizer design. The research partnership follows a December 2025 preprint that specifies both desired outputs: cumulative absorption and intersystem crossing rates linked to reactive-oxygen production. The paper applies proposed fault-tolerant algorithms to BODIPY derivatives, including substitutions that are difficult for standard computational chemistry. This is a sharply defined pharmaceutical calculation, although the announcement reports no new molecular result, hardware run, candidate compound, or development timeline.
The resource estimate belongs to a future machine
The preprint studies active spaces of 11 to 45 spatial orbitals and estimates a need for roughly 180 to 350 logical qubits. Logical qubits are encoded across physical qubits and require error-correction overhead, so that estimate cannot be compared directly with headline physical-qubit counts. Xanadu therefore places the work in fault-tolerant quantum computing, while Professor Alex Brown contributes expertise in photodynamic therapy chemistry and the excited-state processes that classical methods struggle to capture. The partnership joins an algorithm team and a chemistry group around a named failure point in simulation. Its technology readiness remains early because no calculation has yet been reported on suitable hardware or checked against laboratory measurements.
Clinical usefulness still runs through the laboratory
Photodynamic therapy is an established local treatment for selected cancers and precancers, but better photosensitizer calculations must still survive pharmacology, toxicology, formulation, delivery, and trials. A future quantum result would need comparison with measured spectra, photochemical rates, and strong classical baselines. Quentir reads the partnership as a disciplined research bet: the biomedical quantities are prespecified, the molecular class is named, and the resource assumptions are public. Progress will become legible when the workflow reproduces a known molecule's behavior and then ranks unfamiliar candidates well enough to save synthesis cycles.